Venus Concept Announces Establishment of Medical Advisory Board For AI.ME™ -Its Next Generation Robotic Platform
Venus Concept Inc. (NASDAQ: VERO) has announced the establishment of a medical advisory board for AI.ME, its next generation robotic platform for fractional skin resurfacing. The board, comprising six leading physicians, will provide strategic input and clinical recommendations for the technology, which received FDA 510(k) clearance in December 2022.
The advisory board includes renowned dermatologists and plastic surgeons: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman, and Dr. Gilly Munavalli. These experts will play a important role in defining AI.ME's commercialization strategy.
AI.ME is the first and only robotic system cleared by FDA for fractional skin resurfacing. It uses machine vision and AI algorithms to target the skin precisely and predictably. Venus Concept expects to begin clinical engagement with the advisory board members in the coming months, with a commercial launch anticipated in the second half of fiscal year 2024.
Venus Concept Inc. (NASDAQ: VERO) ha annunciato l'istituzione di un consiglio consultivo medico per AI.ME, la sua piattaforma robotica di nuova generazione per il resurfacing frazionale della pelle. Il consiglio, composto da sei medici di spicco, fornirà input strategici e raccomandazioni cliniche per la tecnologia, che ha ricevuto l'approvazione FDA 510(k) nel dicembre 2022.
Il consiglio consultivo include dermatologi e chirurghi plastici rinomati: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman e Dr. Gilly Munavalli. Questi esperti svolgeranno un ruolo fondamentale nella definizione della strategia di commercializzazione di AI.ME.
AI.ME è il primo e unico sistema robotico approvato dalla FDA per il resurfacing frazionale della pelle. Utilizza la visione artificiale e algoritmi di intelligenza artificiale per colpire la pelle in modo preciso e prevedibile. Venus Concept si aspetta di avviare un coinvolgimento clinico con i membri del consiglio consultivo nei prossimi mesi, con un lancio commerciale previsto nella seconda metà dell'anno fiscale 2024.
Venus Concept Inc. (NASDAQ: VERO) ha anunciado el establecimiento de una junta asesora médica para AI.ME, su plataforma robótica de próxima generación para el rejuvenecimiento fraccionado de la piel. La junta, compuesta por seis médicos líderes, proporcionará aportes estratégicos y recomendaciones clínicas para la tecnología, que recibió la aprobación 510(k) de la FDA en diciembre de 2022.
La junta asesor incluye reconocidos dermatólogos y cirujanos plásticos: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman y Dr. Gilly Munavalli. Estos expertos desempeñarán un papel importante en la definición de la estrategia de comercialización de AI.ME.
AI.ME es el primer y único sistema robótico aprobado por la FDA para el rejuvenecimiento fraccionado de la piel. Utiliza visión artificial y algoritmos de IA para tratar la piel de manera precisa y predecible. Venus Concept espera comenzar la interacción clínica con los miembros de la junta asesora en los próximos meses, con un lanzamiento comercial anticipado para la segunda mitad del año fiscal 2024.
베누스 컨셉 주식회사 (NASDAQ: VERO)가 AI.ME에 대한 의료 자문 위원회를 설립한다고 발표했습니다. AI.ME는 분율 피부 재생을 위한 차세대 로봇 플랫폼입니다. 여섯 명의 저명한 의사로 구성된 위원회는 2022년 12월 FDA 510(k) 승인을 받은 이 기술에 대한 전략적 의견과 임상 권고를 제시할 것입니다.
자문 위원회에는 유명한 피부과 의사와 성형외과 의사가 포함되어 있습니다: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman 및 Dr. Gilly Munavalli. 이 전문가들은 AI.ME의 상업화 전략을 정의하는 데 중요한 역할을 할 것입니다.
AI.ME는 FDA에서 승인된 분율 피부 재생을 위한 첫 번째이자 유일한 로봇 시스템입니다. 기계 비전과 AI 알고리즘을 사용하여 피부를 정확하고 예측 가능하게 목표로 삼습니다. 베누스 컨셉은 다음 몇 달 안에 자문 위원회 회원들과 임상 참여를 시작하고 2024 회계 연도 하반기에 상업 출범을 기대하고 있습니다.
Venus Concept Inc. (NASDAQ: VERO) a annoncé la création d'un conseil consultatif médical pour AI.ME, sa plateforme robotique de nouvelle génération pour le resurfaçage fractionné de la peau. Le conseil, composé de six médecins de premier plan, fournira des contributions stratégiques et des recommandations cliniques pour la technologie, qui a reçu l'approbation 510(k) de la FDA en décembre 2022.
Le conseil consultatif comprend des dermatologues et des chirurgiens plastiques renommés : Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman et Dr. Gilly Munavalli. Ces experts joueront un rôle clé dans la définition de la stratégie de commercialisation d'AI.ME.
AI.ME est le premier et unique système robotique approuvé par la FDA pour le resurfaçage fractionné de la peau. Il utilise la vision par ordinateur et des algorithmes d'IA pour cibler la peau de manière précise et prévisible. Venus Concept s'attend à entamer un engagement clinique avec les membres du conseil consultatif dans les mois à venir, avec un lancement commercial prévu dans la seconde moitié de l'exercice fiscal 2024.
Venus Concept Inc. (NASDAQ: VERO) hat die Gründung eines medizinischen Beratungsgremiums für AI.ME angekündigt, seine roboterbasierte Plattform der nächsten Generation für fraktionierte Hautverjüngung. Das Gremium, das aus sechs führenden Ärzten besteht, wird strategische Beiträge und klinische Empfehlungen für die Technologie liefern, die im Dezember 2022 von der FDA die 510(k)-Zulassung erhalten hat.
Das Beratungsgremium umfasst renommierte Dermatologen und plastische Chirurgen: Dr. Glynis Ablon, Dr. Macrene Alexiades, Dr. Eric Bernstein, Dr. James Chao, Dr. Mitchel Goldman und Dr. Gilly Munavalli. Diese Experten werden eine wichtige Rolle bei der Definition der Kommerzialisierungsstrategie von AI.ME spielen.
AI.ME ist das erste und einzige von der FDA zugelassene robotergestützte System für fraktionierte Hautverjüngung. Es verwendet Maschinenvision und KI-Algorithmen, um die Haut präzise und vorhersehbar zu behandeln. Venus Concept erwartet, in den kommenden Monaten klinische Engagements mit den Mitgliedern des Beratungsgremiums zu beginnen, mit einer kommerziellen Einführung, die für die zweite Hälfte des Geschäftsjahres 2024 erwartet wird.
- Establishment of a medical advisory board comprising six leading physicians for AI.ME robotic platform
- AI.ME received FDA 510(k) clearance in December 2022 for fractional skin resurfacing
- AI.ME is the first and only FDA-cleared robotic system for fractional skin resurfacing
- Anticipated commercial launch of AI.ME in the second half of fiscal year 2024
- None.
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the establishment of a medical advisory board for AI.ME, its next generation robotic platform.
The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) in December 2022, for fractional skin resurfacing.
The medical advisory board is composed of six leading practicing physicians:
Dr. Glynis Ablon, MD, FAAD. – Dr. Ablon is a board-certified dermatologist and cosmetic surgeon. Dr. Ablon is an Associate Clinical Professor at UCLA, practicing at both UCLA and LCMH. She is a Fellow of the American Academy of Dermatology, American Society for Laser Medicine and Surgery, and American Society for Dermatologic Surgery. Dr. Ablon is the owner and medical director of Ablon Skin Institute and Research Center, a boutique research center, actively performing over 60 clinical trials.
Dr. Macrene Alexiades, MD, PhD – Dr. Alexiades is a Fellow of the American Academy of Dermatology and American Society for Laser Medicine (ASLMS) and Surgery and a Goldman Circle Member. She has achieved the rare status of Double Board-Certification in Dermatology in the European Union as well as the U.S. Dr. Alexiades is also an Associate Clinical Professor, Yale University and Founder & Director, Dermatology & Laser Surgery Center of New York.
Dr. Eric Bernstein, MD, MSE – Dr. Bernstein is a dermatologist and researcher who has published extensively on the molecular basis of photoaging and the dermatologic uses of energy-based devices. He holds numerous US and international patents. Dr. Bernstein is past president of the ASLMS, is a director for the ASDS, and is Clinical Professor of Dermatology Perelman School of medicine at the University of Pennsylvania and Adjunct Professor of Dermatology at Temple University School of Medicine.
Dr. James Chao, MD, FASC - Dr. Chao is board certified by the American Board of Plastic Surgery and is a Fellow of the American College of Surgeons. He is a member of the American Society of Plastic Surgeons, the American Society for Aesthetic Plastic Surgery, the American Society of Reconstructive Microsurgery and was previously the President of the San Diego Plastic Surgery Society. Dr. Chao serves as plastic and hand surgeon for the San Diego Chargers professional football team and is the recipient of numerous prestigious state and national research awards. In addition, he holds multiple patents of novel devices for plastic and hand surgery.
Dr. Mitchel Goldman, MD – Dr. Goldman is a past president of the American Society for Dermatologic Surgery, the founder and past president of the American College of Phlebology, and Voted #1 Cosmetic Dermatologist in the USA by Newsweek in 2022 and 2023. He is the director of the American Society for Dermatologic Surgery Fellowship Program (which he conceived in 2013) and has hospital affiliations with Scripps Memorial Hospital in La Jolla, California.
Dr. Gilly Munavalli MD, MHS, FACMS – Dr. Munavalli serves as a Clinical Assistant Professor at the Wake Forest University School of Medicine – Department of Dermatology and a Cosmetic Dermatologic Surgery Fellowship Director for the ASDS. He is founder and owner of Dermatology, Laser, and Vein Specialists of the Carolinas in Charlotte, NC, where has been in private practice for almost 20 years.
This diverse team of dermatologists and plastic surgeons, all of whom have extensive clinical experience in aesthetic treatments and authored numerous publications in top peer-reviewed journals, will play an instrumental role in defining AI.ME's commercialization strategy.
AI.ME is the first and only robotic system cleared by FDA for fractional skin resurfacing. It uses machine vision and AI algorithms to target the skin in a precise, pre-planned, selective, and predictable manner. It conducts the treatment via a robotic arm using a smart array of rotating hollow punches, actuated via smart algorithm, to precisely core and excise micro skin-tissue fractions, triggering re-epithelization and collagen deposition.
"We are truly honored to convene this talented group of industry-leading physicians to form the AI.ME medical advisory board," said Dr. Hemanth Varghese, President, and Chief Innovation & Business Officer of Venus Concept. " We believe that this group of experts is well positioned to guide us in realizing AI.ME's full clinical potential and ultimately helping us commercialize AI.ME in a way that transforms patient outcomes and physicians' approach to aesthetic procedures. We expect to begin engaging members of this group to start utilizing AI.ME in the clinical setting in the coming months. We look forward to sharing more exciting news, as we continue to develop and refine this technology in anticipation of commercial launch in the second half of fiscal year 2024."
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 14 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
FAQ
What is Venus Concept's AI.ME and when did it receive FDA clearance?
Who are the members of Venus Concept's (VERO) medical advisory board for AI.ME?
When does Venus Concept (VERO) plan to commercially launch AI.ME?
What makes Venus Concept's (VERO) AI.ME unique in the market?
